Search: onr:"swepub:oai:DiVA.org:uu-183225" > A Randomized, Place...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03570naa a2200517 4500 | |
001 | oai:DiVA.org:uu-183225 | |
003 | SwePub | |
008 | 121023s2012 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1832252 URI |
024 | 7 | a https://doi.org/10.1210/jc.2012-15692 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Orwoll, Eric4 aut |
245 | 1 0 | a A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density |
264 | 1 | b The Endocrine Society,c 2012 |
338 | a print2 rdacarrier | |
520 | a Context: Men with low bone mineral density (BMD) were treated with denosumab.Objective: Our objective was to investigate the effects of denosumab compared with placebo in men with low BMD after 1 yr of treatment.Design, Subjects, and Intervention: This was a placebo-controlled, phase 3 study to investigate the efficacy and safety of denosumab 60 mg every 6 months vs. placebo in men with low BMD.Main Outcome Measure: The primary endpoint was the percent change from baseline in lumbar spine (LS) BMD at month 12.Results: Of the 242 randomized subjects (mean age 65 yr), 228 (94.2%) completed 1 yr of denosumab therapy. After 12 months, denosumab resulted in BMD increases of 5.7% at the LS, 2.4% at the total hip, 2.1% at the femoral neck, 3.1% at the trochanter, and 0.6% at the one third radius (adjusted P <= 0.0144 for BMD percent differences at all sites compared with placebo). Sensitivity analyses done by controlling for baseline covariates (such as baseline testosterone levels, BMD T-scores, and 10-yr osteoporotic fracture risk) demonstrated that the results of the primary endpoint were robust. Subgroup analyses indicate that treatment with denosumab was effective across a spectrum of clinical situations. Treatment with denosumab significantly reduced serum CTX levels at d 15 (adjusted P < 0.0001). The incidence of adverse events was similar between groups.Conclusions: One year of denosumab therapy in men with low BMD was well tolerated and resulted in a reduction in bone resorption and significant increases in BMD at all skeletal sites assessed. | |
700 | 1 | a Teglbjrg, Christence S.4 aut |
700 | 1 | a Langdahl, Bente L.4 aut |
700 | 1 | a Chapurlat, Roland4 aut |
700 | 1 | a Czerwinski, Edward4 aut |
700 | 1 | a Kendler, David L.4 aut |
700 | 1 | a Reginster, Jean-Yves4 aut |
700 | 1 | a Kivitz, Alan4 aut |
700 | 1 | a Lewiecki, E. Michael4 aut |
700 | 1 | a Miller, Paul D.4 aut |
700 | 1 | a Bolognese, Michael A.4 aut |
700 | 1 | a McClung, Michael R.4 aut |
700 | 1 | a Bone, Henry G.4 aut |
700 | 1 | a Ljunggren, Östenu Uppsala universitet,Metabola bensjukdomar4 aut0 (Swepub:uu)osteljun |
700 | 1 | a Abrahamsen, Bo4 aut |
700 | 1 | a Gruntmanis, Ugis4 aut |
700 | 1 | a Yang, Yu-Ching4 aut |
700 | 1 | a Wagman, Rachel B.4 aut |
700 | 1 | a Siddhanti, Suresh4 aut |
700 | 1 | a Grauer, Andreas4 aut |
700 | 1 | a Hall, Jesse W.4 aut |
700 | 1 | a Boonen, Steven4 aut |
710 | 2 | a Uppsala universitetb Metabola bensjukdomar4 org |
773 | 0 | t Journal of Clinical Endocrinology and Metabolismd : The Endocrine Societyg 97:9, s. 3161-3169q 97:9<3161-3169x 0021-972Xx 1945-7197 |
856 | 4 | u https://academic.oup.com/jcem/article-pdf/97/9/3161/9047746/jcem3161.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-183225 |
856 | 4 8 | u https://doi.org/10.1210/jc.2012-1569 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Copy and save the link in order to return to this view